Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

28.89
-0.0200-0.07%
Post-market: 28.920.0297+0.10%19:30 EDT
Volume:830.93K
Turnover:24.00M
Market Cap:4.98B
PE:13.16
High:29.30
Open:28.84
Low:28.51
Close:28.91
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.66
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.81
PE(LYR):12.56

Loading ...

Acadia Pharmaceuticals is Maintained at Perform by Oppenheimer

Dow Jones
·
Aug 06

ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says

MT Newswires Live
·
Aug 06

Acadia Pharmaceuticals, Inc. : Oppenheimer Raises Target Price to $25 from $23

THOMSON REUTERS
·
Aug 05

RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating

MT Newswires Live
·
Aug 05

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

Reuters
·
Aug 05

Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Aug 05

Strong Partner Sales Propel Neuren Pharmaceuticals to Top of Australia Benchmark

Reuters
·
Aug 05

Acadia Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Earnings Flash (ACAD) ACADIA Pharmaceuticals Posts Q2 EPS $0.18, vs. FactSet Est of $0.06

MT Newswires Live
·
Aug 05

Acadia Q2 FY26 Net Income Rises 18% to $32 Million; Net Sales Climb 16% to $308 Million

Reuters
·
Aug 05

Acadia Pharmaceuticals Q2 Revenue Rises on Daybue STIX Demand, Lifts 2026 Outlook

Reuters
·
Aug 05

ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate

Benzinga Earnings
·
Aug 05

Acadia Pharmaceuticals Q2 EPS USD 0.18

Reuters
·
Aug 05

Acadia Pharmaceuticals Outlook FY Revenue USD 1,240-1,300 Million

THOMSON REUTERS
·
Aug 05

Acadia Pharmaceuticals: Lowers Fy2026 R&D Expense Guidance to $355-$380 Mln

THOMSON REUTERS
·
Aug 05

Acadia Pharmaceuticals to Join Canaccord Genuity Growth Conference Fireside Chat

Reuters
·
Jul 31

Earning Preview: ACADIA Pharmaceuticals Q2 revenue is expected to increase by 13%, and institutional views are bullish

Earnings Agent
·
Jul 29

How FDA Fast Track For Remlifanserin In Alzheimer’s Psychosis At ACADIA (ACAD) Has Changed Its Investment Story

Simply Wall St.
·
Jul 28

ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
Jul 25

Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jul 22